Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15203100 | 0.88 | ALDH1A1 (0.30) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL4358831 | 0.87 | FDPS (0.33) | ALDH1A1MAPK1FDPSKDM4ESLC22A1 | |
| SCHEMBL25985224 | 0.80 | — | — | |
| SCHEMBL13412946 | 0.80 | MEN1 (0.37) | ALDH1A1TSHRSLC22A1CYP1A2CHRM2 | |
| SCHEMBL18768240 | 0.77 | — | — | |
| SCHEMBL7888935 | 0.77 | TSHR (0.40) | ALDH1A1TSHRFDPS | |
| SCHEMBL13995952 | 0.77 | FDPS (0.36) | ALDH1A1TSHRMAPK1FDPS | |
| SCHEMBL13995961 | 0.77 | FDPS (0.36) | ALDH1A1TSHRMAPK1FDPS | |
| SCHEMBL6550229 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRMAPK1OPRM1 | |
| SCHEMBL19216014 | 0.77 | PIK3CD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178452-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023077150-A1 | POLYMERS AND NANOPARTICLES FOR INTRAMUSCULAR NUCLEIC ACID DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20200172663-A1 | POLYMER-LIPIDS AND COMPOSITIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-06-04 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | ALDH1A1 1899/4885TSHR 3298/4885MAPK1 364/4885 |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | ALDH1A1 1243/4885TSHR 2262/4885MAPK1 633/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | ALDH1A1 1899/4885TSHR 3298/4885MAPK1 364/4885 |
| US-20200172663-A1 | POLYMER-LIPIDS AND COMPOSITIONS | PHOSPHO1, PEBP1, PBDC1 | ALDH1A1 4610/4885TSHR 4344/4885MAPK1 4285/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | ALDH1A1 1899/4885TSHR 3298/4885MAPK1 364/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | ALDH1A1 2215/4885TSHR 1704/4885MAPK1 66/4885 |
| US-20100055183-A1 | TRIMEPRAZINE AND ETHOPROPAZINE DERIVATIVES FOR PROMOTING BONE GROWTH | IGFBP5, BMP2, HGF | ALDH1A1 1534/4885TSHR 2104/4885MAPK1 2775/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | ALDH1A1 1243/4885TSHR 2262/4885MAPK1 633/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | ALDH1A1 2215/4885TSHR 1704/4885MAPK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.